RenovoRx RNXT 深 滬
等待開盤 09-08 09:30:00 美东时间
2.39
+0.020
+0.84%
華盛通- 最 高2.5396
- 今 開2.35
- 成交量 209.24万股
- 最 低 2.28
- 昨 收 2.37
- 總市值 1.08亿
- 52周最高 2.59
- 市盈率 靜 --
- 換手率 4.64%
- 52周最低 0.7006
- 委 比 -8.22%
- 總股本 4512.95万
- 歷史最高 16.74
- 量 比 0.67
- 振 幅 10.95%
- 歷史最低 0.5306
- 每 手 1
- 風險率 0.22%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多These low-priced stocks are flashing overbought signals
Several sub-$10 stocks are flashing elevated momentum signals, with a handful already entering traditionally overbought territory as recent rallies push their Relative Strength Index readings toward t...
09-05 00:19
The best Quant-rated stocks trading below $10 right now
Seeking Alpha's Quant Rating system has identified a fresh group of sub-$10 stocks that rank among the highest-rated names in its universe, underscoring that low-priced shares can still exhibit strong...
09-04 18:51
美股前瞻 | 苹果换帅！库克明日正式卸任；美伊互袭，油价急涨4%！三大期指齐挫；SK海力士被曝考虑英特尔代工
苹果换帅！库克明日正式卸任；美伊互袭，油价急涨4%！三大期指齐挫；HBM供应链生变？SK海力士被曝考虑英特尔代工>>
08-31 20:16
美股大行评级 | 潜在涨幅768.26%！Ascendiant Capital维持RenovoRx(RNXT)"买入"评级，目标价上调至14.5美元
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从14美元升至14.5美元；HC Wainwright & Co.：维持Generate Biomedicines"买入"评级，目标价从25美元升至30美元
08-31 18:14
Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $14.5
Ascendiant Capital analyst Edward Woo maintains RenovoRx (NASDAQ:RNXT) with a Buy and raises the price target from $14 to $14.5.
08-28 18:50
RenovoRx regains Nasdaq compliance
RenovoRx (RNXT) announced on Friday that it has received a Nasdaq notification, confirming that the company has regained compliance with the minimum bid price requirement for continued listing on the ...
08-21 21:12
RenovoRx Earnings Call: Record Growth, Rising Risks
Renovorx, Inc. (($RNXT)) has held its Q2 earnings call. Read on for the main hi...
08-21 08:27
RenovoRx Regains Nasdaq Compliance on Minimum Bid Price
The latest update is out from RenovoRx ( ($RNXT) ). On December 31, 2025, Renov...
08-21 05:14
RenovoRx Says USPTO Issues Notice Of Allowance For Patent Application Titled Methods And Apparatuses For Delivery Of Therapeutic Materials For The Treatment Of Cancer
RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice o...
08-20 20:34
RenovoRx Q2 Adj. EPS $(0.05) Beats $(0.07) Estimate, Sales $909.000K Beat $716.500K Estimate
RenovoRx (NASDAQ:RNXT) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.07) by 28.57 percent. This is a 37.5 percent increase over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $909.000 thousand whic...
08-13 04:09
